Germany · Delayed Price · Currency is EUR Cassava Sciences Statistics
Total Valuation
FRA:PX91 has a market cap or net worth of EUR 87.21 million. The enterprise value is -3.98 million.
| Market Cap | 87.21M |
| Enterprise Value | -3.98M |
Important Dates
The next estimated earnings date is Tuesday, March 3, 2026.
| Earnings Date | Mar 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 48.31M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +7.58% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 11.02% |
| Owned by Institutions (%) | 28.68% |
| Float | 42.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.25 |
| P/TBV Ratio | 1.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.04 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.06 |
Financial Position
The company has a current ratio of 2.27
| Current Ratio | 2.27 |
| Quick Ratio | 2.22 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -85.44% and return on invested capital (ROIC) is -35.32%.
| Return on Equity (ROE) | -85.44% |
| Return on Assets (ROA) | -24.80% |
| Return on Invested Capital (ROIC) | -35.32% |
| Return on Capital Employed (ROCE) | -85.85% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -3.01M |
| Employee Count | 30 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.19% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -37.19% |
| 50-Day Moving Average | 2.46 |
| 200-Day Moving Average | 2.06 |
| Relative Strength Index (RSI) | 35.63 |
| Average Volume (20 Days) | 188 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.23 |
Income Statement
| Revenue | n/a |
| Gross Profit | -36.88M |
| Operating Income | -59.77M |
| Pretax Income | -90.37M |
| Net Income | -90.37M |
| EBITDA | -59.06M |
| EBIT | -59.77M |
| Earnings Per Share (EPS) | -1.87 |
Balance Sheet
The company has 90.41 million in cash and n/a in debt, with a net cash position of 90.41 million.
| Cash & Cash Equivalents | 90.41M |
| Total Debt | n/a |
| Net Cash | 90.41M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 69.52M |
| Book Value Per Share | 1.44 |
| Working Capital | 51.87M |
Cash Flow
In the last 12 months, operating cash flow was -71.40 million and capital expenditures -116,765, giving a free cash flow of -71.51 million.
| Operating Cash Flow | -71.40M |
| Capital Expenditures | -116,765 |
| Free Cash Flow | -71.51M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:PX91 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.58% |
| Shareholder Yield | -7.58% |
| Earnings Yield | -103.62% |
| FCF Yield | -82.00% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 10, 2017. It was a reverse split with a ratio of 0.1428571429.
| Last Split Date | May 10, 2017 |
| Split Type | Reverse |
| Split Ratio | 0.1428571429 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |